Table 1 Baseline Characteristics
From: The role of Asprosin in patients with dilated cardiomyopathy
Variable | All patients (n = 50) | Asprosin | P value | |
|---|---|---|---|---|
Low group (n = 25) | High group (n = 25) | |||
Age, y | 55 ± 10 (35–78) | 55 ± 11 (35–78) | 54 ± 9 (36–71) | 0.98 |
Female gender, n (%) | 7 (14.0%) | 4 (16.0%) | 3 (12.0%) | > 0.99 |
Body mass index, kg/m2 | 25.8 ± 4.3 | 25.2 ± 4.6 | 26.4 ± 4.1 | 0.44 |
Hypertension, n (%) | 14 (28.0%) | 6 (24.0%) | 8 (32.0%) | 0.75 |
Diabetes mellitus, n (%) | 12 (24.0%) | 6 (24.0%) | 6 (24.0%) | > 0.99 |
Systolic blood pressure, mmHg | 115 ± 21 | 112 ± 22 | 118 ± 19 | 0.25 |
Heart rate, bpm | 80 ± 16 | 82 ± 16 | 79 ± 18 | 0.47 |
NYHA class III or IV, n (%) | 15 (30.0%) | 7 (28.0%) | 8 (32.0%) | > 0.99 |
COPD, n (%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | > 0.99 |
Atrial fibrillation, n (%) | 17 (34.0%) | 8 (32.0%) | 9 (36.0%) | > 0.99 |
LV mass index, g/m2 | 344.9 ± 104.6 | 358.0 ± 110.7 | 331.8 ± 98.6 | 0.46 |
LV end-diastolic volume index, mL/m2 | 248.9 ± 74.9 | 248.1 ± 81.3 | 249.7 ± 69.7 | 0.99 |
LV ejection fraction, % | 27.1 ± 9.9 | 26.5 ± 10.7 | 27.7 ± 9.2 | 0.63 |
Mitral E/A ratio | 1.4 ± 0.9 | 1.4 ± 0.7 | 1.4 ± 1.1 | 0.85 |
ACEI/ARB, n (%) | 44 (88.0%) | 23 (92.0%) | 21 (84.0%) | 0.67 |
Beta-blockers, n (%) | 42 (84.0%) | 21 (84.0%) | 21 (84.0%) | > 0.99 |
Spironolactone, n (%) | 30 (60.0%) | 15 (60.0%) | 15 (60.0%) | > 0.99 |
Loop diuretics, n (%) | 36 (72.0%) | 19 (76.0%) | 17 (68.0%) | 0.75 |
Digoxin, n (%) | 21 (42.0%) | 10 (40.0%) | 11 (44.0%) | > 0.99 |
BNP, pg/mL | 1073 ± 1199 | 1208 ± 1370 | 955 ± 1046 | 0.74 |
eGFR, mL/min/1.73 m2 | 75.4 ± 24.5 | 77.1 ± 22.9 | 73.7 ± 26.3 | 0.73 |
Creatinine, mg/dL | 1.5 ± 1.8 | 1.7 ± 2.4 | 1.2 ± 0.7 | 0.94 |
Cholesterol, mg/dL | 156.4 ± 35.0 | 147.4 ± 31.3 | 165.5 ± 36.8 | 0.09 |
Sugar, mg/dL | 103.8 ± 24.9 | 99.6 ± 16.7 | 108.2 ± 31.1 | 0.43 |
HbA1C, % | 6.2 ± 1.1 | 6.1 ± 1.0 | 6.4 ± 1.3 | 0.54 |